ArticleFrontiers in pharmacology2024

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.

Kang-Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.